Government · 2 deals

BARDA

Disclosed deals

Every published round BARDA took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.

Company	Stage	Announced	Amount	Role	Alongside	Sources
Vaxxas	Series D+	Aug 2025	$49m	Participant	SPRIM Global Investments LGT Crestone OneVentures Brandon Capital-Hostplus	Startup Daily (Tue 23 Dec 2025), SmartCompany (Tue 23 Dec 2025), Startup Daily (Tue 14 Oct 2025), Cut Through Venture, Startup Daily (Fri 29 Aug 2025), SmartCompany (Fri 29 Aug 2025), Startup Daily (Tue 26 Aug 2025), Business News Australia
Vaxxas	Grant	14 Jan 2025	$3.2m	Lead	Vaxxas from the US Biomedical Advanced Research and Development Authority	Business News Australia, Brandon BioCatalyst (Tue 18 Feb 2025), Brandon Capital (Tue 18 Feb 2025), @AuManufacturing (Thu 23 Jan 2025), @AuManufacturing (Mon 20 Jan 2025), Brandon BioCatalyst (Tue 14 Jan 2025), Brandon Capital (Tue 14 Jan 2025)

Portfolio

Companies BARDA has backed in a published round, and companies whose existing shares it bought off another holder.

Company	What it does	First invested	Rounds	Led
Vaxxas		14 Jan 2025, Grant	2	1

Funds

Fund closes reported for BARDA, as distinct from the investments it has made.

Fund	Announced	Committed	Target	Close	Sources
No fund closes recorded for BARDA yet.

Portfolio companies acquired

Companies BARDA has backed that another company then bought. An exit for the holding, not a deal BARDA did.

Company	Bought by	Kind	Announced	Price
No portfolio company of BARDA is recorded as having been acquired.

People

Name	Role	Sources

Something wrong? Tell us

BARDA

Disclosed deals

Portfolio

Funds

Portfolio companies acquired

People

Coverage

ENA Respiratory Begins Part B Dosing

ENA Respiratory Receives USPTO Notice of Allowance for Two Patents Covering TLR2 Agonists and Rhinovirus-Mediated COPD Exacerbations

ENA Respiratory Appoints Melissa Faris to Board

ENA Respiratory Announces Dosing of First Participants in Phase II Study of INNA-051 Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections

Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery

Vaxxas Completes Enrollment for Largest Clinical Trial of High-Density Microarray Patch (HD-MAP) For Vaccine Delivery

ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

Manufacturing news briefs — stories you might have missed

Vaxxas Named Stage Winner of United States’ BARDA Prize to Advance Microarray Patches for Vaccination

Vaxxas Named Stage Winner of United States' BARDA Prize to Advance Microarray Patches for Vaccination

Vaxxas licenses RSV vaccine candidate

ENA Respiratory Announces Extension of U.S. Department of Defense Funding for Novel Prophylactic Antiviral

Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles and Rubella Vaccine Delivered Using its Proprietary High-Density Microarray Skin Patch; Plan for Phase I/II Trial in The Gambia, Africa

Vaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine

Vaxxas Appoints Dr. Rochelle Chaiken as Chief Medical Officer

Vaxxas Appoints Dr. Rochelle Chaiken as Chief Medical Officer

Vaxxas initiates Phase I study for needle-free seasonal influenza vaccine delivered using High-Density Microarray Patch (HD-MAP)

Coming in from the cold: needle-free patch technology for mRNA vaccines aims to end need for frozen storage and improve access

Vaxxas Raises US$23 million (A$34 million) to Clinically Advance Needle-Free Vaccines, Including a Next-Generation COVID-19 Vaccine Candidate

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)

Vaxxas Announces Initiation of Phase I Clinical Study of First Needle-Free COVID-19 Vaccine Delivered Using High-Density Microarray Patch (HD-MAP)